The Full Wiki

More info on NNC 63-0532

NNC 63-0532: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

NNC 63-0532
Systematic (IUPAC) name
methyl [8-(1-naphthylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetate
Identifiers
CAS number 250685-44-0
ATC code  ?
PubChem 9803475
Chemical data
Formula C 27H29N3O3  
Mol. mass 443.536 g/mol
SMILES eMolecules & PubChem
Synonyms NNC 63-0532
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

NNC 63-0532 is an opioid drug used in scientific research. It acts as a potent and selective agonist for the nociceptin receptor, also known as the ORL-1 receptor.[1][2] The function of this receptor is still poorly understood, but it is thought to have roles in many disorders such as pain, drug addiction, development of tolerance to opioid drugs, and psychological disorders such as anxiety and depression. Research into the function of this receptor is an important focus of current pharmaceutical development and selective agents such as NNC 63-0532 are essential for this work.[3]

References

  1. ^ Thomsen C, Hohlweg R. (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. British Journal of Pharmacology. 2000 Nov;131(5):903-8. PMID 11053209
  2. ^ Guerrini R, Carra' G, Calo' G, Trapella C, Marzola E, Rizzi D, Regoli D, Salvadori S. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity. Journal of Peptide Research. 2004 Jun;63(6):477-84. PMID 15175020
  3. ^ Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Current Drug Targets. 2007 Jan;8(1):117-35. PMID 17266536
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message